PARPi‐containing regimen vs non‐PARPi regimen
Response rate · locally advanced or metastatic breast cancer
PARPi‐containing regimen may leads to higher response Rate compared with non‐PARPi regimen (low certainty).
1 finding from 1 review
- PARP (Poly ADP‐Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer 2021 · Cochrane Headline outcomes onlyRR 1.39 [1.24, 1.54]5 studies · 1185 participantsLow